Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC and Bristol-Myers Squibb Company Announce Additional Results from SAVOR Cardiovascular Outcomes Trial


Thursday, 26 Sep 2013 02:00am EDT 

AstraZeneca PLC and Bristol-Myers Squibb Company announced on September 26, 2013 additional results from the SAVOR cardiovascular outcomes trial, which found no increased rate of hypoglycemia among patients treated with Onglyza (saxagliptin) compared to placebo when added to metformin monotherapy and higher rates of hypoglycemia only in the Onglyza group compared to the placebo group among patients taking sulfonylureas, agents known to cause hypoglycemia, at baseline. Additionally, a greater percentage of patients taking Onglyza reached their target HbA1c without hypoglycemia, except patients who were treated with sulfonylreas alone at baseline. These findings are consistent with previous studies of Onglyza. Results were presented at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain. 

Company Quote

830.54
9.12 +1.11%
19 Aug 2014